Shanghai Haohai Biological Technology (HKG:6826, SHA:688366) recorded a 1% rise in attributable profit for the year 2024 to 420.4 million yuan from 416.1 million yuan a year prior, a March 21 filing with the Hong Kong bourse said.

Earnings per share were 1.80 yuan in the year, up from 1.75 yuan in the last fiscal year.

Revenue rose by 1.7% to 2.68 billion yuan in the period from 2.63 billion yuan a year prior.

The ophthalmic products manufacturer attributed the higher profit mainly to a rise in operating revenue.

The firm proposed a final dividend of 0.60 yuan per share for the year.